Abstract
MS is characterized by chronic and immune-mediated inflammatory lesions of the brain white matter, disseminated in time and space. As the technology improved over the next three decades, MRI quickly grew to become the single most important paraclinical diagnostic and monitoring tool available. A lesion will be defined as having a high T2/FLAIR signal ≥ 3 millimeters in diameter. The purpose of this study, witch includes 95 patients, was to investigate the benefit of a computer assisted detection reading using combined automated co-registration and lesion color-coding method approach, over a conventional reading approach in follow-up examinations of patients with MS, especially regarding diagnostic accuracy, inter/intra-reader agreement and required reading time. The impact of the use of a structured report on these variables will also be evaluated. The main judgment criteria will be : diagnostic accuracy (effectiveness) to assess the progression-activity of the disease based on the appearance of a T2w-FLAIR hyperintensity or a T1w enhancement on the follow-up examination, compared between consensus corrected CADR and CR readings.The reading of the examinations will be made by radiologists and radiology technician.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Comite d'Ethique pour la Recherche en Imagerie Medicale CERIM IRB Number: CRM-2206-271
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
no data available